Policy Notices

• Reminder: NIH Natural Disaster Policy Hurricane Isaias, Derecho
  (NOT-OD-20-161)
  National Institutes of Health
  

• Notice of Correction to Eligibility in NIH Funding Opportunity Announcements
  (NOT-OD-20-171)
  National Institutes of Health
  

General Notices

• Notice of Expiration of NOT-EB-20-006 "Notice of Special Interest (NOSI): Small Business Research and Development of Biomedical Technologies for Coronavirus Disease 2019 (COVID-19)"
  (NOT-EB-20-014)
  National Institute of Biomedical Imaging and Bioengineering
  

• Findings of research misconduct
  (NOT-OD-20-167)
  National Institutes of Health
  

• NCATS Announces Plans to Publish the ASPIRE 2020 Reduction-to-Practice Challenge Prize Competition
  (NOT-TR-20-035)
  National Center for Advancing Translational Sciences
  

• RESCINDED - Notice of NIH Participation in the Ecology and Evolution of Infectious Diseases Program
  (NOT-TW-20-007)
  John E. Fogarty International Center
  National Institute of Allergy and Infectious Diseases
  National Institute of General Medical Sciences
  

• Request for Information (RFI) on Encouraging AAALAC International-Accredited Institutions to Use Sections of the AAALAC Program Description in the OLAW Animal Welfare Assurance
  (NOT-OD-20-169)
  National Institutes of Health
  

Notice of Changes to Funding Opportunities

• Notice of Change to RFA-AG-21-026 Preclinical Development of Novel Therapeutics Targeting Aging Mechanisms (SBIR U44 Clinical Trial Not Allowed)
  (NOT-AG-20-048)
  National Institute on Aging
  

• Notice of Change to Research and Related Other Project Information (Pilot and Feasibility Program) Instructions for RFA-DK-20-002: NIDDK Centers for Diabetes Translation Research (P30 Clinical Trial Optional)
  (NOT-DK-20-044)
  National Institute of Diabetes and Digestive and Kidney Diseases
  

• Notice of Change to Funding Opportunity Description of RFA-DK-20-011 "Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Clinical Centers (U01 Clinical Trial Required)"
  (NOT-DK-20-045)
  National Institute of Diabetes and Digestive and Kidney Diseases
  

• Notice of Change to Funding Opportunity Description of RFA-DK-20-012 "Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)"
  (NOT-DK-20-046)
  National Institute of Diabetes and Digestive and Kidney Diseases
  

• Notice of Change to Application Instructions for PAR-20-220, Institutional Network Award for Promoting Kidney, Urologic, and Hematologic Research Training (U2C-Clinical Trial Not Allowed)
  (NOT-DK-20-047)
  National Institute of Diabetes and Digestive and Kidney Diseases
  

• Notice of NIGMS Participation in NOT-ES-20-018 Notice of Special Interest: Promoting Fundamental and Applied Research in Inflammation Resolution
  (NOT-GM-20-046)
  National Institute of General Medical Sciences
  

• Notice of Change: Emphasizing an Opportunity for New Institutional Applicants in Response to PAR-19-204 Centers of Excellence in Genomic Science (RM1 Clinical Trial Optional)
  (NOT-HG-20-056)
  National Human Genome Research Institute
  

• Notice of NHLBI Participation in PAR-19-051 "Emerging Global Leader Award (K43 Independent Clinical Trial Required)"
  (NOT-HL-20-809)
  National Heart, Lung, and Blood Institute
  

• Notice of Application Due Date Change for RFA-HL-20-021 "Trans-Agency Blood-Brain Interface Program (R61/R33 - Clinical Trials Not Allowed)"
  (NOT-HL-20-813)
  National Heart, Lung, and Blood Institute
  

• Notice to Extend RFA-MH-19-135 - BRAIN Initiative: Development of Novel Tools to Probe Cell-Specific and Circuit-Specific Processes in Human and Non-Human Primate Brain (UG3/UH3 Clinical Trial Optional)
  (NOT-MH-20-080)
  National Institute of Mental Health
  National Center for Complementary and Integrative Health
  National Eye Institute
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Biomedical Imaging and Bioengineering
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Drug Abuse
  National Institute on Deafness and Other Communication Disorders
  National Institute of Neurological Disorders and Stroke
  

• Notice to Extend RFA-MH-20-135 BRAIN Initiative: Tools to Facilitate High-Throughput Microconnectivity Analysis (R01 Clinical Trial Not Allowed)
  (NOT-MH-20-081)
  National Institute of Mental Health
  National Center for Complementary and Integrative Health
  National Eye Institute
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Biomedical Imaging and Bioengineering
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Drug Abuse
  National Institute on Deafness and Other Communication Disorders
  National Institute of Neurological Disorders and Stroke
  

• Notice of Change to Key Dates for RFA-NS-18-011 "Translational Neural Devices (UG3/UH3 Clinical Trial Required)"
  (NOT-NS-20-101)
  National Institute of Neurological Disorders and Stroke
  

• Notice of Change to Key Dates for RFA-NS-18-012 "Translational Neural Devices (U44 Clinical Trial Required)"
  (NOT-NS-20-102)
  National Institute of Neurological Disorders and Stroke
  

• Notice of Change to Key Dates for PAR-18-940 Clinical and Translational Science Award (U54 Clinical Trial Optional)
  (NOT-TR-20-036)
  National Center for Advancing Translational Sciences
  

Notices of Special Interest

• Notice of Special Interest: Administrative Supplements for Connecting Pre-mortem Clinical Information with Post-Mortem Brain Analysis
  (NOT-NS-21-001)
  National Institute of Neurological Disorders and Stroke
  

Funding Opportunities

• Mentored Career Development Program (K01) for Early Stage Investigators Using Nonhuman Primate Research Models (K01 Independent Clinical Trial Not Allowed)
  (PAR-20-258)
  National Institute of Allergy and Infectious Diseases
  National Center for Complementary and Integrative Health
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs
  Application Receipt Date(s): Standard dates apply. The first standard due date for this FOA is October 12, 2020. Alltypes of non-AIDS applicationsallowed for this funding opportunity announcement are due on these dates.
  
  

• New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R01 Clinical Trial Required)
  (PAR-20-273)
  National Institute on Drug Abuse
  Application Receipt Date(s): Only accepting applications for the AIDS Application Due dates listed below
  
  

• New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R34 - Clinical Trial Optional )
  (PAR-20-274)
  National Institute on Drug Abuse
  Application Receipt Date(s): Only accepting applications for the AIDS Application Due Dates listed below.
  
  

• NCI Research Specialist (Core-based Scientist) Award (R50 Clinical Trial Not Allowed)
  (PAR-20-287)
  National Cancer Institute
  Application Receipt Date(s): January 4, 2021 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s) Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  
  

• NCI Research Specialist (Laboratory-based Scientist) Award (R50 Clinical Trial Not Allowed)
  (PAR-20-288)
  National Cancer Institute
  Application Receipt Date(s): January 4, 2021 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s) Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  
  

• NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
  (PAR-20-292)
  National Cancer Institute
  Application Receipt Date(s): October 20, 2020; February 19, 2021; June 21, 2021; October 20, 2021; February 22, 2022; June 21, 2022
  
  

• Clinical Translation of Activated Optical Fluorescence Methods and Technologies for Sensitive Cancer Detection in Vivo (R01 Clinical Trial Optional)
  (PAR-20-295)
  National Cancer Institute
  Application Receipt Date(s): February 10, 2021; October 13, 2021
  
  

• NIOSH Centers of Excellence for Total Worker Health (U19)
  (PAR-20-297)
  National Institute for Occupational Safety and Health
  Application Receipt Date(s): February 3, 2021; October 29, 2021; October 28, 2022; October 30, 2023 No late applications will be accepted for this FOA
  
  

• NCI Pediatric In Vivo Testing Program (U01 Clinical Trial Not Allowed)
  (RFA-CA-20-034)
  National Cancer Institute
  Application Receipt Date(s): November 09, 2020 No late applications will be accepted for this Funding Opportunity Announcement.
  
  

• NCI Pediatric In Vivo Testing Program Coordinating Center (U24 Clinical Trial Not Allowed)
  (RFA-CA-20-041)
  National Cancer Institute
  Application Receipt Date(s): November 9, 2020
  
  

• Glioblastoma Therapeutics Network (U19 Clinical Trial Required)
  (RFA-CA-20-047)
  National Cancer Institute
  Application Receipt Date(s): November 19, 2020 No late applications will be accepted for this Funding Opportunity Announcement. All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  
  

• The NCI Predoctoral to Postdoctoral Fellow Transition Award (F99/K00)
  (RFA-CA-20-048)
  National Cancer Institute
  Application Receipt Date(s): November 18, 2020 All applications are due, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. No late applications will be accepted for this FOA.
  
  

• Toward ElucidAting MechanismS of HIV Pathogenesis within the Mission of the NIDDK (Pathogenesis TEAMS) (R01 Clinical Trial Optional)
  (RFA-DK-20-022)
  National Institute of Diabetes and Digestive and Kidney Diseases
  Application Receipt Date(s): Only accepting applications for the AIDS Application Due Date(s) listed below.
  
  

• RESolution of InflammaTion in EnvirOnmentally Related diseasE (RESTORE) (R01 Clinical Trial Not Allowed)
  (RFA-ES-20-013)
  National Institute of Environmental Health Sciences
  Application Receipt Date(s): February 11, 2021
  
  

• Center without Walls for Molecular Mechanisms of Neurodegeneration in Frontotemporal Degeneration (FTD) (U54 Clinical Trial not Allowed)
  (RFA-NS-21-003)
  National Institute of Neurological Disorders and Stroke
  National Institute on Aging
  Application Receipt Date(s): November 2, 2020 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  
  

• Multi-disciplinary Machine-assisted, Genomic Analysis and Clinical Approaches to Shortening the Rare Diseases Diagnostic Odyssey (UG3/UH3 Clinical Trial Not Allowed)
  (RFA-TR-20-030)
  National Center for Advancing Translational Sciences
  Application Receipt Date(s): November 12, 2020